-
In case you missed it | Which abstracts from
#ASH19 will change clinical practice in AML? Our Steering Committee provided their opinions on the practice-changing abstracts presented, available here as a free downloadable resource: https://buff.ly/30YlimO#leusmpic.twitter.com/qsRRtb7lep
-
Marketing authorization application validation of KTE-X19 followed promising data from the phase II ZUMA-2 trial investigating its efficacy and safety. Read a summary of the interim results presented at
#ASH19 here
https://lymphomahub.com/medical-information/results-from-the-phase-ii-zuma-2-trial-car-t-therapy-for-mcl … #lymsm@ASH_hematology https://twitter.com/lymphomahub/status/1224679001014308864 …pic.twitter.com/AwbYRSO4Rp
-
MURANO Trial
#ASH19@abbvie: Mohamed Zaki, MD of@abbvie discusses the phase 3 MURANO trial. ________ Read here: https://www.oncologytube.com/video/new-long-term-data-continues-to-demonstrate-progression-free-survival-and-overall-survival-benefits-with-venclexta-venclyxto-venetoclax-combination-in-patients-with-relapsed-refractory-ch-1 … http://dlvr.it/RPPT1L pic.twitter.com/0yHzLCJLOU
-
CARTITUDE-1: How is This Different from Others?
@MountSinaiNYC@DMadduri#ASH19#ASH: Deepu Madduri, MD@DMadduri of@MountSinaiNYC@IcahnMountSinai discusses the CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against b-cell… http://dlvr.it/RPNYv8 pic.twitter.com/xxK3uGOKRH
-
Dose Optimization Portion of the Phase 2 PRIMO Study in Relapsed or Refractory PTCL
#ASH19@sloan_kettering: Steven Horwitz, MD of@sloan_kettering discusses the phase 2 PRIMO study. _______ Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the… http://dlvr.it/RPMph4 pic.twitter.com/2Evmn8TZuP
-
At
#ASH19,@Virajn, COTA’s VP of Life Sciences, spoke with@AJMC_Journal on the growing understanding & acceptance of#RWD and how it is used in#clinical research. Hear his insight below as it relates to clinical trials & recent initiatives: https://bit.ly/39awxLY pic.twitter.com/rAh89LuuQb
-
Read the results of a study presented at
#ASH19 showing that mutated lymphopoiesis may increase the risk of developing B cell and PC oligoclonality leading to the expansion of MM PCs https://multiplemyelomahub.com/medical-information/mutated-lymphopoiesis-and-b-cell-oligoclonality-can-precede-the-pathogenesis-of-multiple-myeloma-and-persist-blob:https://teams.microsoft.com/977f0c60-4f99-4ebc-a460-f561a85f9cb2in-patients-with-negative-measurable-residual-disease …#mmsm#myelomapic.twitter.com/PyzodJbo2j
-
The
@MM_Hub Steering Committee members shared the top abstracts from#ASH19 that they believe could have the greatest impact on clinical practice! Follow the link for their comments#mmsm
https://buff.ly/3b1ONZD pic.twitter.com/JSy12KHuqP
-
Read a summary of the results from the dose escalation phase of a first-in-human study of REGN1979 in patients with R/R B-NHL
https://buff.ly/2Uc1JWJ #ASH19#lymsmpic.twitter.com/DFiyXTaZa5
-
Early relapse in MCL | A short duration of 1st remission was associated with an increased risk of death, irrespective of front-line therapy intensity in patients with mantle cell lymphoma. Read more here: https://buff.ly/36I6Qk0
#ASH19#lymsmpic.twitter.com/CZ8d35V95y
-
My fellow Dr Kat Lewis presently eloquently on aggressive lymphoma highlights from
#ASH19#WiL#lymSMpic.twitter.com/GdAWyzuLIJ
-
Check and download the full
#ASH19 CML AN Congress Report summarizing: •Update on stopping CML treatment •Discontinuation of TKIs in children with CML •New drugs for CML, generic Imatinib and other topics •CML Educational session https://www.cmladvocates.net/download/scientific-conferences/ash-2019/968-ash19-cml-advocates-network-congress-report/file …@ASH_hematologypic.twitter.com/YY1e0DxAXQ
-
CML is truly one of our
#cancer success stories:
Identification of #BCR-ABL
Development of #TKIs
#Patients Care revolution Globally, however, deep challenges remain. Check our#ASH19#CML#Education Session summary. https://www.cmladvocates.net/110-news/965-summary-of-the-cml-educational-session-from-ash-2019 …#Research#PatientAdvocacypic.twitter.com/OPmFceqJwU
-
At
#ASH19 Ali Bazarbachi spoke to the@GvHD_Hub about novel prophylactic therapies available before and after transplantation to reduce the risk of#GvHD. Watch the interview here
https://buff.ly/2PgcIeW #gvhdsmpic.twitter.com/dwttKZW7Vf
-
From
#ASH19 - 4 year analysis confirms sustained benefit of time-limited Venetoclax-Rituximab in relapsed/refractory Chronic Lymphocytic Leukemia#leusm#lymsm Abstract here: http://bit.ly/2RExZ3c pic.twitter.com/9StB5YjPHs
-
No, that was disclosed at
#ASH19. 2 or 3 of those 5 deaths look like they might have been treatment-related$AUTLpic.twitter.com/TI4Qvxyh0v
-
Maintenance Therapy With CC-486 Extends Survival of Adults With AML
@theNCI https://www.cancerhealth.com/blog/maintenance-therapy-cc486-extends-survival-adults-aml …#ASH19 -
@wendster discussing the HD14 (early unfav Hodgkin) data presented at#ash19. 2xescBEACOPP + 2xABVD + RT better PFS than 4xABVD+RT. BUT the unfav group in H10 did just as well without all receiving v intensive chemo.#lymsmpic.twitter.com/iJXxgKp6qK
-
New PreClinical Data for its IL-15 Agonist, NKTR-255
#ASH19#ASH: Loui Madakamutil, PhD of Nektar Therapeutics discusses new preclinical Ddta for its IL-15 agonist, NKTR-255 at ASH 2019. ___________ Read here: https://www.oncologytube.com/video/nektar-therapeutics-announces-presentation-of-new-preclinical-data-for-its-il-15-agonist-nktr-255-at-the-american-society-of-hematology-ash-2019-annual-meeting … http://dlvr.it/RP3dcy pic.twitter.com/AZcvTlEFYa
-
Newly posted! Check out our practice aids on
#lymphoma from our recently released activity from#ASH19. http://bit.ly/2Na0W4a#BTKinhibitor
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.